CT
Citius Oncology, Inc.
CTOR · NASDAQ
$1.14 +10.68% (+$0.11)
1M +53.27%
Market Cap $94.8M
P/E Ratio -
Div. Yield -
ROE 102.98%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/B 2.35x
P/S 13.35x
EV/FFO N/A
Growth
65 /100
Stable Book val. growth 7.35%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 665.63%
Gross margin 53.13%
FCF margin 277.34%
Quality
1 /100
Poor ROA 41.09%
ROIC 89.09%
Asset turnover 0.06x
Debt
51 /100
Moderate Int. coverage -82.99x
Debt/Equity 0.25x
Current ratio 0.73x
Stability
7 /100
Unstable Profitable years 0
Beta 3.53x
EPS volatility 69.16%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CTOR
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Leonard L. Mazur
Employees
285
Headquarters
Cranford
Prihajajoči dogodki
17 DEC.
Earnings
Upcoming earnings report